Everything below concerns Melanotan II. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-25. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Most reptiles are insectivorous or carnivorous and have simple and comparatively short digestive tracts due to meat being fairly simple to break down and digest. Digestion is slower than in mammals, reflecting their lower resting metabolism and their inability to divide and masticate their food. Their poikilotherm metabolism has very low energy requirements, allowing large reptiles like crocodiles and large constrictors to live from a single large meal for months, digesting it slowly. While modern reptiles are predominantly carnivorous, during the early history of reptiles several groups produced some herbivorous megafauna: in the Paleozoic, the pareiasaurs; and in the Mesozoic several lines of dinosaurs. Today, turtles are the only predominantly herbivorous reptile group, but several lines of agamas and iguanas have evolved to live wholly or partly on plants. Herbivorous reptiles face the same problems of mastication as herbivorous mammals but, lacking the complex teeth of mammals, many species swallow rocks and pebbles (so called gastroliths) to aid in digestion: The rocks are washed around in the stomach, helping to grind up plant matter. Fossil gastroliths have been found associated with both ornithopods and sauropods, though whether they actually functioned as a gastric mill in the latter is disputed. Salt water crocodiles also use gastroliths as ballast, stabilizing them in the water or helping them to dive. A dual function as both stabilizing ballast and digestion aid has been suggested for gastroliths found in plesiosaurs.
Molecular: HCHO + hν → H2 + CO (λ < 360 nm) Radical: HCHO + hν → H + HCO (λ < 330 nm) The H and HCO radicals react with the atmospheric O2 to form hydroperoxyl (HO2) radicals, giving a net radical channel of:
Soybean seed contains 18–19% oil. To extract soybean oil from seed, the soybeans are cracked, adjusted for moisture content, rolled into flakes, and solvent-extracted with commercial hexane. The oil is then refined, blended for different applications, and sometimes hydrogenated. Soybean oils, both liquid and partially hydrogenated, are exported abroad, sold as "vegetable oil", or end up in a wide variety of processed foods. As of 2022, China produces 29% of the world's soybean oil and the United States is the second largest producer at 21%.
Sources: en.wikipedia.org
In group 14, both metallic and covalent bonding become possible. In a diamond crystal, covalent bonds between carbon atoms are strong, because they have a small atomic radius and thus the nucleus has more of a hold on the electrons. Therefore, the bonding orbitals that result are much lower in energy than the antibonding orbitals, and there is no overlap, so electrical conduction becomes impossible: carbon is a nonmetal. However, covalent bonding becomes weaker for larger atoms and the energy gap between the bonding and antibonding orbitals decreases. Therefore, silicon and germanium have smaller band gaps and are semiconductors at ambient conditions: electrons can cross the gap when thermally excited. (Boron is also a semiconductor at ambient conditions.) The band gap disappears in tin, so that tin and lead become metals. As the temperature rises, all nonmetals develop some semiconducting properties, to a greater or lesser extent depending on the size of the band gap. Thus metals and nonmetals may be distinguished by the temperature dependence of their electrical conductivity: a metal's conductivity lowers as temperature rises (because thermal motion makes it more difficult for the electrons to flow freely), whereas a nonmetal's conductivity rises (as more electrons may be excited to cross the gap). Elements in groups 15 through 17 have too many electrons to form giant covalent molecules that stretch in all three dimensions.
Hacker, Barton C.; Grimwood, James M. (1977). On the Shoulders of Titans - A History of Project Gemini (SP-4203) (PDF) (Report). NASA. Retrieved January 2, 2026. Spaceflight Mission Patches website NASA NSSDC spacecraft details NASA Gemini 4 press kit (65-158) (PDF) (Report). May 21, 1965. Archived from the original (PDF) on June 21, 2009. "GEMINI 4 - Ed White Spacewalk- Dual Camera, Real Speed, Restored Audio" on YouTube The short film Four Days of Gemini 4 is available for free viewing and download at the Internet Archive.
Those whose half-lives exceed a few percent of the age of the Earth (about 4.6×109 years) survive from its formation and are remnants of nucleosynthesis that occurred in stars before the formation of the Solar System. For example, the isotope 23892U (t1/2 = 4.463×109 years) of uranium is still fairly abundant in nature, but the shorter-lived isotope 23592U (t1/2 = 0.704×109 years) is now 138 times rarer. 35 of these primordial radionuclides have been identified (see List of nuclides and Primordial nuclide for details). Radiogenic nuclides (such as 22688Ra (t1/2 = 1600 years), an isotope of radium) that are formed by radioactive decay. They occur in the decay chains of primordial isotopes of uranium or thorium. Some of these nuclides are very short-lived, such as isotopes of francium. There exist about 50 of these daughter nuclides that have half-lives too short to be primordial, and which exist in nature solely due to decay from longer lived radioactive primordial nuclides. Nuclides that are continuously being made in another fashion that is not simple spontaneous radioactive decay (i.e., only one atom involved with no incoming particle) but instead involves a natural nuclear reaction. These occur when atoms react with natural neutrons (from cosmic rays, spontaneous fission, or other sources), or are bombarded directly with cosmic rays. The latter, if non-primordial, are called cosmogenic nuclides. Other types of natural nuclear reactions produce nuclides that are said to be nucleogenic nuclides.
Sources: en.wikipedia.org
) increases as [S] increases. However, as [S] gets higher, the enzyme becomes saturated with substrate and the initial rate reaches Vmax, the enzyme's maximum rate. In the Michaelis–Menten kinetic model of a single-substrate reaction there is an initial bimolecular reaction between the enzyme E and substrate S to form the enzyme–substrate complex ES. The rate of enzymatic reaction increases with the increase of the substrate concentration up to a certain level called Vmax; at Vmax, increase in substrate concentration does not cause any increase in reaction rate as there is no more enzyme (E) available for reacting with substrate (S). Here, the rate of reaction becomes dependent on the ES complex and the reaction becomes a unimolecular reaction with an order of zero. Though the enzymatic mechanism for the unimolecular reaction
== Mechanism == The underlying mechanism involves injury and inflammation of epithelial and sub-epithelial cells. These cells then lose the ability to repair the tissue, in particular they lose the ability to regenerate the epithelial or outermost layer, leading to the excess growth of cells that cause scarring. There are multiple pathways of the disease including fibrotic, lymphocytic, and antibody-mediated that have been described. However, while each pathway has a more unique starting point and cause, the result is still injury and inflammation leading to scarring of the lung tissue. The scarred tissue then makes the expiration phase of respiration more difficult, leading to air not being expelled from the lungs. This is termed "air-trapping", which can be seen on medical imaging. Since the scarring is non-reversible, the disease generally does not improve over time, and depending on the inciting can progress to death.
== History == Methenamine was first discovered as a chemical compound in 1859. It was introduced for medical use as a urinary antiseptic under the name Urotropin in 1895. The drug was described as rapidly sterilizing and thereby restoring putrid and pus-filled urine to a normal appearance and constitution. A combination of methenamine with salicylic acid was also developed and introduced the same year. Methenamine was only used as a urinary antiseptic in cases of acidic urine, whereas boric acid was used to treat UTIs with alkaline urine. The drug name methenamine, a contraction of the chemical or scientific name hexamethylenetetramine, was formally introduced and designated by the United States Pharmacopeia (USP) by 1925 and replaced the prior name of the drug that was being used of hexamethylenamine. The alternative drug name hexamine was introduced in the British Pharmacopoeia (BP) by 1914 to be used instead of the commercial name Urotropin. Interest in methenamine declined after the discovery of the antibiotic penicillin in 1928 and it has been described as a "forgotten drug". However, there was a surge of interest in methenamine from the 1950s to the 1980s. The drug was formally approved by the Food and Drug Administration (FDA) for medical use in the United States in 1967. The topical form of methenamine for treatment of hyperhidrosis was introduced around 1965. Subsequently, there was another decline in interest in methenamine from 1980 until 2010.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.